Johnson & Johnson has announced that new preliminary results from a South African study has shown that the homologous booster shot of the company's Covid-19 vaccine (Ad26.COV2.S) demonstrated 85 per cent effectiveness against the virus-related hospitalisation in South Africa after Omicron became the dominant variant. The South African Phase 3b Sisonke study, conducted by the
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced new preliminary results from the South African Phase 3b Sisonke study which showed...
Two new studies of a Johnson & Johnson COVID-19 vaccine booster showed promise against the omicron variant at a time when public health officials